

**MnVFC Announcement**

Date: January 16, 2024

To: MnVFC Providers

From: MnVFC Program

**Re: Abrysvo for MnVFC**

Please route to:

- Clinical supervisor
- Medical director
- Clinic manager
- Clinic staff
- Pharmacy
- Vaccine staff

Abrysvo, the Pfizer RSV vaccine that is approved for pregnant people has been added to the MnVFC contract. Pregnant people who are eligible for MnVFC (medical assistance, uninsured, underinsured at some sites) can get MnVFC RSV vaccine.

Abrysvo should be given to pregnant people at 32 to 36 weeks gestation from September through January to help protect the newborn infant from RSV. Babies born at least 2 weeks after pregnant person's vaccination should not receive the monoclonal antibody Beyfortus (nirsevimab) except in rare circumstances.

Abrysvo has been added to the MnVFC order form. It is available in individual single dose vials. Please order only a limited number of doses this year since we are close to the end of the vaccination season.

For sites that have multiple RSV products (Beyfortus/nirsevimab, Abrysvo or Arexvy), make sure to educate staff on the different uses and indications to avoid vaccination errors. Also, remember that Arexvy (GSK) is not approved for pregnant people.

Resources:

- [CDC: For Healthcare Professionals: RSV \(Respiratory Syncytial Virus\) \(\[www.cdc.gov/rsv/clinical/index.html#maternal-vaccines\]\(https://www.cdc.gov/rsv/clinical/index.html#maternal-vaccines\)\)](https://www.cdc.gov/rsv/clinical/index.html#maternal-vaccines).
- [CDC: Vaccine Information Statement: Respiratory Syncytial Virus Vaccine VIS \(\[www.cdc.gov/vaccines/hcp/vis/vis-statements/rsv.pdf\]\(https://www.cdc.gov/vaccines/hcp/vis/vis-statements/rsv.pdf\)\)](https://www.cdc.gov/vaccines/hcp/vis/vis-statements/rsv.pdf).

MnVFC Program

651-201-5522 or 1-800-657-3970

[www.health.state.mn.us/vfc](http://www.health.state.mn.us/vfc)

[health.mnvfc@state.mn.us](mailto:health.mnvfc@state.mn.us)